Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fludarabine phosphate
Drug ID BADD_D00915
Description Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Indications and Usage For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Marketing Status Prescription; Discontinued
ATC Code L01BB05
DrugBank ID DB01073
KEGG ID D01907
MeSH ID C042382
PubChem ID 30751
TTD Drug ID D0TO2R
NDC Product Code 45963-621; 53183-7841; 59923-604; 51916-310; 33656-0015; 63323-192; 24201-237; 25021-242; 45963-609; 58623-0043; 59605-7136
Synonyms fludarabine phosphate | fludarabine 5'-monophosphate | 9 beta-D-arabinofuranosyl-2-fluoroadenine monophosphate | fludarabine monophosphate | FaraAMP | fluoro-ara-AMP | 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)- | F-ara-AMP | NSC 312887 | NSC-312887 | Beneflur | Fludara
Chemical Information
Molecular Formula C10H13FN5O7P
CAS Registry Number 75607-67-9
SMILES C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraesthesia17.02.06.005--
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Pericardial effusion02.06.01.002--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis24.05.03.001; 12.02.01.002--
Platelet count decreased13.01.04.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Progressive multifocal leukoencephalopathy17.16.02.002; 11.05.05.001--Not Available
Proteinuria20.02.01.011--
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Pulmonary haemorrhage24.07.01.016; 22.02.04.003--
Pyrexia08.05.02.003--
Radial nerve palsy17.09.02.004--Not Available
Rash23.03.13.001--Not Available
Renal failure20.01.03.005--Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin cancer23.08.02.002; 16.03.02.002--Not Available
Sleep disorder19.02.04.001--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Stomatitis07.05.06.005--
Supraventricular tachycardia02.03.03.012--
Thrombocytopenia01.08.01.002--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages